Abstract
A 63-year-old woman with pulmonary adenocarcinoma (stage IIIB) that was positive for an epidermal growth factor receptor (EGFR) mutation and an anaplastic lymphoma kinase (ALK) rearrangement was treated with erlotinib as the first-line treatment, resulting in a stable disease. Due to skin rashes, fatigue and anorexia, erlotinib was suspended on erlotinib day 44. Alectinib was administered as the second-line treatment, exhibiting a partial response. On alectinib day 56, drug-induced lung injury forced suspension of alectinib, which was cured with corticosteroid therapy. ALK-tyrosine kinase inhibitors may be more effective for patients positive for both EGFR mutation and ALK rearrangement than other agents.
Keywords:
ALK rearrangement; EGFR mutation; non-small cell lung cancer.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / genetics*
-
Adenocarcinoma of Lung
-
Adrenal Cortex Hormones / therapeutic use*
-
Anaplastic Lymphoma Kinase
-
Carbazoles / adverse effects
-
Carbazoles / therapeutic use*
-
Cough / drug therapy
-
Cough / etiology
-
ErbB Receptors / genetics*
-
Erlotinib Hydrochloride / adverse effects
-
Erlotinib Hydrochloride / therapeutic use*
-
Female
-
Fever / drug therapy
-
Fever / etiology
-
Humans
-
Hypoxia / drug therapy
-
Hypoxia / etiology
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics*
-
Middle Aged
-
Mutation
-
Piperidines / adverse effects
-
Piperidines / therapeutic use*
-
Receptor Protein-Tyrosine Kinases / genetics*
-
Treatment Outcome
Substances
-
Adrenal Cortex Hormones
-
Carbazoles
-
Piperidines
-
Erlotinib Hydrochloride
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
ErbB Receptors
-
Receptor Protein-Tyrosine Kinases
-
alectinib